[et_pb_section bb_built=”1″ module_class=”page-section” _builder_version=”3.22.7″ background_color=”rgba(0,0,0,0.4)” background_image=”https://axspa.relief-as.com/wp-content/uploads/2019/05/MLG_New-Bg-Images_About.png” parallax=”on” custom_margin=”0px||” custom_padding=”0px||” custom_css_before=”content:%22%22; display:block; background:rgba(0,0,0,0.5); position:absolute; left:0; right:0; top:0; bottom:0;” custom_css_main_element=”position:relative;”][et_pb_row use_custom_gutter=”on” custom_padding=”250px||0px|||” custom_padding_phone=”200px||” custom_margin=”|auto|50px|auto||” custom_padding_last_edited=”on|phone” module_class=”first-div” _builder_version=”3.22.7″ background_image=”https://divignerdev.com/ra-relief/wp-content/uploads/2019/05/MLG_about_banner.svg” width=”100%” max_width=”100%” custom_margin_phone=”||40px” custom_margin_last_edited=”on|desktop”][et_pb_column type=”4_4″][et_pb_post_title meta=”off” featured_image=”off” text_color=”light” text_background=”on” text_bg_color=”rgba(0,0,0,0.75)” _builder_version=”3.22.7″ title_font=”|700|||||||” title_font_size=”45px” title_letter_spacing=”1px” text_orientation=”center” max_width=”900px” module_alignment=”center”]
[/et_pb_post_title][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”3.22.7″ width=”100%” max_width=”1300px”][et_pb_column type=”4_4″][et_pb_text _builder_version=”3.22.7″ text_font=”|300|||||||” header_font=”|700|||||||” header_2_font=”|700|||||||” header_2_font_size=”35px” header_2_line_height=”1.2em” header_3_font=”|700|||||||” header_3_font_size=”30px” text_orientation=”center” background_layout=”dark” custom_margin=”||50px|||” custom_margin_phone=”||70px” custom_margin_last_edited=”on|phone”]
The RELIEF Initiative
The RELIEF initiative aims to provide clinicians and patients with up-to-date information on the use of current and emerging glucagon-like peptide-1 (GLP-1) receptor agonists in the management of type 2 diabetes. By compiling the latest information from clinical trials and treatment guidelines, we aim to provide users with a convenient resource that improves clinical outcomes and quality of life for patients. Through participation in our online and live offerings, our goal is to empower healthcare providers to personalize therapy based on patient-specific factors and improve the standard of care for people with type 2 diabetes. The Clinician Toolkit provides information on treatment guidelines, a summary of important clinical trials, and tips on managing adverse events with GLP-1 receptor agonists. The Patient Toolkit is a handy resource that educates patients about their disease and empowers them to engage in healthcare decisions.
Thank you for visiting our website. Please explore the Clinician Toolkit and Patient Toolkit links above for cutting-edge information on the treatment and management of type 2 diabetes with GLP-1 receptor agonists.
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
